Author(s): Yingsakmongkol N
Abstract Share this page
Abstract OBJECTIVE: To study clinical outcomes and safety of WF I 0 as an adjunct to standard treatment for diabetic foot ulcers (DFU) and to determine the optimal number of WF I 0 cycles that should be administered. METHOD: A prospective, open-label study of WF I 0 adjunct to standard treatment for severe DFU but salvageable foot was carried out between July 2009 and June 20 I 0. Patients were classified into three groups, according to common clinical presentations: neuropathic ulcer, ischaemic ulcer and severely infected ulcer. Ulcer assessments were monitored using the wound severity score (WSS; range 0-16).The clinical outcomes at 24 weeks were defined as 'good' (ulcer achieved endpoint [WSS=0-1 ]), 'fair'(improved from baseline [WSS=2-4]) and 'poor' (not improved or worsened [WSS > 4]). RESULTS: From a total of 129 patients, 21 ( 16\%) presented with neuropathic ulcers, 49 (38\%) with ischaemic ulcers and 59 (46\%) with severely infected ulcers.AII neuropathic ulcers achieved either a good or fair outcome, with 81\% achieving a good outcome, as did 49\% and 81\% of ischaemic and severely infected ulcers, respectively. Minor amputations were necessary for 14 patients (I I\%), but no major amputation was required. Twenty seven patients (21 \%) had transient reduction of haematocrit after WF I 0 therapy. One hundred and one patients (78 \%) received only I cycle of WF I 0. CONCLUSION: WF I 0 as an adjunct to standard DFU treatment showed good clinical outcomes in the neuropathic ulcer group and the severely infected ulcer group. A side effect of WF I 0, transient reduction of haematocrit, was observed in 21\% of patients. Most patients required only one cycle of WF I 0.
This article was published in J Wound Care
and referenced in Journal of Diabetes & Metabolism